TISSUE REGENIX GROUP PLC ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2017 TISSUE REGENIX GROUP IS A 
Z GROUP LOSS FOR THE YEAR OF £9.4M
PERFORMANCE SEE PAGES 07 TO 18 A Tissue Regenix Group Company
A Tissue Regenix Group Company
A Tissue Regenix Group Company
A Tissue Regenix Group Company
A Tissue Regenix Group Company
STRATEGIC REPORT TISSUE REGENIX GROUP HAS ESTABLISHED A GROWING PORTFOLIO 
The Group is organised into three divisions for internal management, reporting and decision-making –  
by the closing market value of the ordinary shares of the Company 
The Group operates a share option plan, under which certain 
with the trustee of the Tissue Regenix Group Employee Share Trust 
The remuneration of the main Board Directors of Tissue Regenix who served in the year to 31 December 2017 was:
In addition, a certain Director holds employee share scheme interests in the Company.
Directors’ interests in the shares of the Company, including family interests at 31 December 2017 were:
Directors’ interests in shares owned jointly with the Trustees of the Tissue Regenix Group Employee Benefit Trust (EBT) and in share options 
years after the date of grant, subject to the Company’s share price reaching 25 
proportions three years after the date of grant, subject to the Company’s share 
Full details of the Group and Company’s share capital movements 
Directors’ interests in the shares of the Company, including  
share capital of Tissue Regenix Group plc were:
*  Includes 10,740,000 shares held jointly by the Director and the Tissue 
the Group and parent Company financial statements in accordance 
Company law requires the directors to prepare Group and parent 
Company financial statements for each financial year.
parent Company financial statements, the Directors are required to: 
{ assess the Group and parent Company’s ability to continue as a 
We have audited the financial statements of Tissue Regenix Group 
and parent company statement of changes in equity, the group 
and parent company statement of financial position, the group and 
31 December 2017 and of the Group’s loss for the year  
TO THE MEMBERS OF TISSUE REGENIX GROUP PLC THE RISK OUR RESPONSE
Materiality for the group financial statements as a whole was set at 
The loss for the year arises from the Group’s continuing operations.
The financial statements of Tissue Regenix Group plc are audited consolidated financial statements for the year ended 31 December 2017.
The Group financial statements consolidate the financial statements of Tissue Regenix Group plc and the entities it controls, being its 
Cost of sales in the Group’s financial statements comprises cost of goods sold and external commissions payable.
At each reporting date, the Group reviews the carrying amounts of its property, plant and equipment and intangible assets to determine 
Where an employee acquires an interest in shares in the Company jointly with the Tissue Regenix Employee Share Trust, the fair value 
Tissue Regenix Group entered a joint venture in January 2016 establishing GBM-V GmbH, a company in Germany.
relate to the future volatility of the share price of comparable companies, the Group’s expected dividend yields, risk free interest rates and 
At the date of authorisation of these financial statements, the following standards and interpretations relevant to the Group that have not 
The following accounting standards that are due to be adopted in the next year will or may have an impact on the Group’s future financial 
In order to assess the impact of the implementation of the new revenue standard on the Group’s consolidated financial statements, 
No Standards or Interpretations adopted in the year had any material impact on the financial statements of the Group.
The following table provides disclosure of the Group’s revenue by geographical market based on location of the customer:
The Directors recognise that the operations of the Group are dynamic and therefore this position will be monitored as the Group develops.
The average monthly number of persons (including Directors) employed by the Group during the period was:
* The Group has not recognised a deferred tax asset relating to these losses as their recoverability is uncertain.
Group’s overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse 
The Group does not consider that any changes in fair value of financial assets or liabilities in the year are attributable to credit risk.
The Group seeks to manage liquidity risk to ensure that sufficient liquidity is available to meet foreseeable needs and to invest cash assets 
as the first part of the expansion plan for the US group to process in-house human tissue products in the US.
close relationship between CellRight and Tissue Regenix businesses will be mutually beneficial including shared resources in manufacturing, 
Since the acquisition date, CellRight has contributed £2,166,000 to Group revenues and a profit of £277,000 to Group income.
has acquired shares in the Group jointly with a number of employees.
The fair value benefit received on share options granted is measured using the Binomial model taking in to account the effects of the vesting 
Expected vesting life of EBT shares and options (years) 4 – 4
options and employee interests in jointly owned EBT shares which are not exercised within 10 years from the date of grant will expire.
The Company’s key management personnel comprise only the Directors of the Group.
During the year the Group entered into the following transactions in which the Directors had an interest:
The principal accounting policies adopted are the same as for those set out in the Group’s financial statements.
The audit fee for the Company is set out in note 4 to the Group’s financial statements.
significant effects on the carrying amounts of the assets and liabilities in the parent company financial statements are described below:
1. To receive the Company’s annual accounts, strategic report and Directors’ and Auditor’s reports for the year ended 31 December 2017.
FINANCIALS TISSUE REGENIX GROUP PLC
TISSUE REGENIX GROUP PLC ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2017